F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021

Rhea-AI Summary

F-star Therapeutics (NASDAQ: FSTX) announced an investor conference call set for March 29, 2021, at 9:00 a.m. EDT. The management team will discuss 2020 financial results and provide a corporate update. Interested participants can join via a live webcast or call 1-833-471-0868 for US/Canada and 1-914-987-7751 for international attendees. A replay of the call will be available from March 30, 2021, for 90 days. F-star is focused on developing bispecific antibodies for innovative cancer therapies, aiming to improve patient outcomes.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that it will host a full year 2020 investor conference call and webcast on Monday, March 29, 2021 at 9:00 a.m. EDT. The F-star Therapeutics management team, including Eliot Forster, CEO and Darlene Deptula-Hicks, CFO, will discuss 2020 financial results and provide a corporate update.

To access the call, participants may join via a live webcast on the Investors and News section of the F-star Therapeutics website, under Events and Presentations or participants can dial 1-833-471-0868 in the US/Canada or 1-914-987-7751 for International calls, at least 10 minutes prior to the start of the call.

A replay of the conference call will be available beginning March 30, 2021 and may be accessed in the Investors & News/Events and Presentations section on the F-star Therapeutics website for 90 days.

About F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit https://www.f-star.com/ and follow us on LinkedIn and Twitter.

For further information, please contact:

For investor inquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com 

For media inquiries
Helen Shik
Shik Communications LLC
617-510-4373
Shik.Helen10@gmail.com 

FAQ

When will F-star Therapeutics host its investor conference call?

F-star Therapeutics will host its investor conference call on March 29, 2021, at 9:00 a.m. EDT.

How can I access the investor conference call for FSTX?

Participants can access the F-star Therapeutics investor conference call via a live webcast on their website or by calling 1-833-471-0868 in the US/Canada.

What will be discussed during the F-star Therapeutics conference call?

The F-star Therapeutics management team will discuss the 2020 financial results and provide a corporate update during the call.

Is there a replay available for the F-star Therapeutics conference call?

Yes, a replay of the F-star Therapeutics conference call will be available starting March 30, 2021, for 90 days.

What is the focus of F-star Therapeutics in cancer treatment?

F-star Therapeutics is focused on developing bispecific antibodies to improve immunotherapy outcomes for cancer patients.